Forbes April 18, 2022
Rita Numerof

Our firm has been measuring progress along the journey to population health for 7 years. That progress has been painfully slow. While the pandemic did shine a light on why we need a predictable revenue model in healthcare delivery focused on prevention and primary care, bailouts and rescues have kept a dying fee-for-service model on continued life support. Population health represents a real opportunity for providers to improve not only the health and well-being of those they serve, but also their own financial health.

However, and despite general agreement with this outlook among industry insiders, our research highlights that most providers have yet to commit themselves to a new model. Instead, the general theme has been to blame others for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma, Pharma / Biotech, Population Health Mgmt
USP Calls for Pharmacists to Volunteer to Advance Global Public Health Standards
Pharma Pulse 1/20/25: Leveraging Data Standards, The Good and Bad News About Melanoma & more
What’s Driving Pharma Investors in 2025
Navigating 2025: Three Key Trends Shaping the Future of Pharma
GoodRx: The Average Price Per Insulin Unit Dropped 42%

Share This Article